PMID- 34940846
OWN - NLM
STAT- MEDLINE
DCOM- 20220420
LR  - 20220606
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 107
IP  - 5
DP  - 2022 Apr 19
TI  - Value of Somatostatin Receptor PET/CT in Patients With MEN1 at Various Stages of 
      Their Disease.
PG  - e2056-e2064
LID - 10.1210/clinem/dgab891 [doi]
AB  - CONTEXT: Despite the growing evidence of the clinical value of somatostatin 
      receptor (SSTR) positron emission tomography (PET) in the evaluation of 
      neuroendocrine tumors (NETs), its role remains to be clarified at different time 
      points in the journey of patients with multiple endocrine neoplasia type 1 
      (MEN1). The rarity of the disease is however a significant impediment to 
      prospective clinical trials. OBJECTIVE: The goals of the study were to assess the 
      indications and value of SSTR PET/computed tomography (CT) in patients with MEN1. 
      METHODS: We retrospectively included patients from 7 French expert centers for 
      whom data on SSTR PET/CT and morphological imaging performed at the same period 
      were available. Detection rates of PET study were analyzed. RESULTS: One hundred 
      and 8 patients were included. SSTR PET/CT was performed at screening (n = 33), 
      staging (n = 34), restaging (n = 37), and for peptide receptor targeted 
      radiotherapy selection (n = 4). PET detected positive pancreatic lesions in 91% 
      of cases at screening, with results comparable with magnetic resonance imaging 
      but superior to CT (P = .049). Metastases (mostly lymph node [LN]) were present 
      at the screening phase in 28% of cases, possibly due to the suboptimal value of 
      screening morphological imaging in the assessment of nodal metastases and/or a 
      long delay between imaging studies. SSTR PET/CT was considered superior or 
      complementary to the reference standard in the assessment of LN or distant 
      metastases in the vast majority of cases and regardless of the clinical scenario. 
      CONCLUSION: This study shows the potential added value of SSTR PET in the 
      assessment of MEN1-associated NETs and provides great impetus toward its 
      implementation in the evaluation of patients with MEN1.
CI  - (c) The Author(s) 2021. Published by Oxford University Press on behalf of the 
      Endocrine Society. All rights reserved. For permissions, please e-mail: 
      journals.permissions@oup.com.
FAU - Mennetrey, Clement
AU  - Mennetrey C
AD  - Department of Nuclear Medicine, La Timone University Hospital, CERIMED, 
      Aix-Marseille University, France.
FAU - Le Bras, Maelle
AU  - Le Bras M
AD  - Department of Endocrinology, Diabetology and Nutrition, l'institut du thorax, CHU 
      Nantes, Nantes, France.
FAU - Bando-Delaunay, Aurelie
AU  - Bando-Delaunay A
AD  - Universite de Paris, Department of Nuclear Medicine, Beaujon University Hospital 
      (APHP.Nord), Clichy, France.
FAU - Al-Mansour, Laure
AU  - Al-Mansour L
AD  - Department of Oncology, Hospices Civils of Lyon, France.
FAU - Haissaguerre, Magalie
AU  - Haissaguerre M
AD  - Department of Endocrinology, Haut Leveque University Hospital, Bordeaux, France.
FAU - Batisse-Lignier, Marie
AU  - Batisse-Lignier M
AD  - Department of Nuclear Medicine, Centre Jean Perrin, Clermont-Ferrand, France.
FAU - Ouvrard, Eric
AU  - Ouvrard E
AD  - Department of Nuclear Medicine and Molecular Imaging - Institut de Cancerologie 
      de Strasbourg Europe (ICANS), IPHC, UMR 7178, CNRS/University of Strasbourg, 
      France.
FAU - Ansquer, Catherine
AU  - Ansquer C
AD  - Nuclear Medicine Department, CHU de Nantes, Hotel-Dieu, Nantes, France.
FAU - Walter, Thomas
AU  - Walter T
AD  - Department of Oncology, Hospices Civils of Lyon, France.
FAU - de Mestier, Louis
AU  - de Mestier L
AD  - Universite de Paris, Department of Gastroenterology-Pancreatology, Beaujon 
      University Hospital (APHP. Nord), Clichy, France.
FAU - Kelly, Antony
AU  - Kelly A
AD  - Department of Nuclear Medicine, Centre Jean Perrin, Clermont-Ferrand, France.
FAU - Tlili, Ghoufrane
AU  - Tlili G
AD  - Department of Nuclear Medicine, Haut Leveque University Hospital, Bordeaux, 
      France.
FAU - Giraud, Sophie
AU  - Giraud S
AD  - Genetics Department, Hospices Civils de LYON (HCL), University Hospital, East 
      Pathology Center, LYON.
FAU - North, Marie-Odile
AU  - North MO
AD  - Department of Genetic & Molecular Biology, Hopital Cochin, Assistance 
      Publique-Hopitaux de Paris, Paris, France.
FAU - Odou, Marie-Francoise
AU  - Odou MF
AD  - Laboratory of biochemistry and molecular biology, Lille university hospital, 
      Inserm U1286, France.
FAU - Goichot, Bernard
AU  - Goichot B
AD  - Department of Internal Medicine, University hospitals of Strasbourg, France.
FAU - Cuny, Thomas
AU  - Cuny T
AD  - Department of Endocrinology, Conception Hospital, Aix-Marseille University, 
      France.
FAU - Loundou, Anderson
AU  - Loundou A
AUID- ORCID: 0000-0003-4301-9476
AD  - Department of Public health, Aix-Marseille University, Marseille, France.
FAU - Romanet, Pauline
AU  - Romanet P
AD  - Aix Marseille Univ, APHM, INSERM, MMG, Laboratory of Molecular Biology Hospital 
      La Conception, Marseille, France.
FAU - Imperiale, Alessio
AU  - Imperiale A
AD  - Department of Nuclear Medicine and Molecular Imaging - Institut de Cancerologie 
      de Strasbourg Europe (ICANS), IPHC, UMR 7178, CNRS/University of Strasbourg, 
      France.
FAU - Taieb, David
AU  - Taieb D
AUID- ORCID: 0000-0002-0400-7600
AD  - Department of Nuclear Medicine, La Timone University Hospital, CERIMED, 
      Aix-Marseille University, France.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 0 (Receptors, Somatostatin)
SB  - IM
MH  - Humans
MH  - *Multiple Endocrine Neoplasia Type 1/diagnostic imaging
MH  - *Neuroendocrine Tumors/diagnostic imaging
MH  - Positron Emission Tomography Computed Tomography/methods
MH  - Positron-Emission Tomography/methods
MH  - Prospective Studies
MH  - Receptors, Somatostatin
MH  - Retrospective Studies
OTO - NOTNLM
OT  - MEN1
OT  - gallium 68-labeled somatostatin analogs
OT  - genetics
OT  - neuroendocrine tumors
OT  - positron emission tomography
OT  - somatostatin receptors
EDAT- 2021/12/24 06:00
MHDA- 2022/04/21 06:00
CRDT- 2021/12/23 12:49
PHST- 2021/09/20 00:00 [received]
PHST- 2021/12/24 06:00 [pubmed]
PHST- 2022/04/21 06:00 [medline]
PHST- 2021/12/23 12:49 [entrez]
AID - 6481711 [pii]
AID - 10.1210/clinem/dgab891 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2022 Apr 19;107(5):e2056-e2064. doi: 
      10.1210/clinem/dgab891.